Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women

Carol J. Fabian, Bruce F. Kimler, Joseph E. Donnelly, Debra K. Sullivan, Jennifer R. Klemp, Brian K. Petroff, Teresa A. Phillips, Trina Metheny, Sonya Aversman, Hung Wen Yeh, Carola M. Zalles, Gordon Mills, Stephen D. Hursting

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We conducted a phase II feasibility study of a 6-month behavioral weight loss intervention in postmenopausal overweight and obese women at increased risk for breast cancer and the effects of weight loss on anthropomorphic, blood, and benign breast tissue biomarkers. 67 women were screened by random peri-areolar fine-needle aspiration, 27 were registered and 24 participated in the interventional phase. The 24 biomarker evaluable women had a median baseline BMI of 34.2 kg/m2 and lost a median of 11 % of their initial weight. Significant tissue biomarker modulation after the 6-month intervention was noted for Ki-67 (if restricted to the 15 women with any Ki-67 at baseline, p = 0.041), adiponectin to leptin ratio (p = 0.003); and cyclin B1 (p = 0.001), phosphorylated retinoblastoma (p = 0.005), and ribosomal S6 (p = 0.004) proteins. Favorable modulation for serum markers was observed for sex hormone-binding globulin (p < 0.001), bioavailable estradiol (p < 0.001), bioavailable testosterone (p = 0.033), insulin (p = 0.018), adiponectin (p = 0.001), leptin (p < 0.001), the adiponectin to leptin ratio (p < 0.001), C-reactive protein (p = 0.002), and hepatocyte growth factor (p = 0.011). When subdivided by <10 or >10 % weight loss, change in percent total body and android (visceral) fat, physical activity, and the majority of the serum and tissue biomarkers were significantly modulated only for women with >10 % weight loss from baseline. Some factors such as serum PAI-1 and breast tissue pS2 (estrogen-inducible gene) mRNA were not significantly modulated overall but were when considering only those with >10 % weight loss. In conclusion, a median weight loss of 11 % over 6 months resulted in favorable modulation of a number of anthropomorphic, breast tissue and serum risk and mechanistic markers. Weight loss of 10 % or more should likely be the goal for breast cancer risk reduction studies in obese women.

Original languageEnglish (US)
Pages (from-to)119-132
Number of pages14
JournalBreast Cancer Research and Treatment
Volume142
Issue number1
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

Weight Loss
Breast
Biomarkers
Serum
Breast Neoplasms
Cyclin B1
S 6
Sex Hormone-Binding Globulin
Intra-Abdominal Fat
Retinoblastoma
Adiponectin
Plasminogen Activator Inhibitor 1
Feasibility Studies
Risk Reduction Behavior
Fine Needle Biopsy
Leptin
Estrogens
Exercise
Weights and Measures
Messenger RNA

Keywords

  • Breast risk biomarkers with weight loss
  • Energy balance
  • RPFNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fabian, C. J., Kimler, B. F., Donnelly, J. E., Sullivan, D. K., Klemp, J. R., Petroff, B. K., ... Hursting, S. D. (2013). Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women. Breast Cancer Research and Treatment, 142(1), 119-132. https://doi.org/10.1007/s10549-013-2730-8

Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women. / Fabian, Carol J.; Kimler, Bruce F.; Donnelly, Joseph E.; Sullivan, Debra K.; Klemp, Jennifer R.; Petroff, Brian K.; Phillips, Teresa A.; Metheny, Trina; Aversman, Sonya; Yeh, Hung Wen; Zalles, Carola M.; Mills, Gordon; Hursting, Stephen D.

In: Breast Cancer Research and Treatment, Vol. 142, No. 1, 01.11.2013, p. 119-132.

Research output: Contribution to journalArticle

Fabian, CJ, Kimler, BF, Donnelly, JE, Sullivan, DK, Klemp, JR, Petroff, BK, Phillips, TA, Metheny, T, Aversman, S, Yeh, HW, Zalles, CM, Mills, G & Hursting, SD 2013, 'Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women', Breast Cancer Research and Treatment, vol. 142, no. 1, pp. 119-132. https://doi.org/10.1007/s10549-013-2730-8
Fabian, Carol J. ; Kimler, Bruce F. ; Donnelly, Joseph E. ; Sullivan, Debra K. ; Klemp, Jennifer R. ; Petroff, Brian K. ; Phillips, Teresa A. ; Metheny, Trina ; Aversman, Sonya ; Yeh, Hung Wen ; Zalles, Carola M. ; Mills, Gordon ; Hursting, Stephen D. / Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women. In: Breast Cancer Research and Treatment. 2013 ; Vol. 142, No. 1. pp. 119-132.
@article{a97a6ecdab2b4bc68dc702b94adb3c04,
title = "Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 {\%} weight loss in postmenopausal women",
abstract = "We conducted a phase II feasibility study of a 6-month behavioral weight loss intervention in postmenopausal overweight and obese women at increased risk for breast cancer and the effects of weight loss on anthropomorphic, blood, and benign breast tissue biomarkers. 67 women were screened by random peri-areolar fine-needle aspiration, 27 were registered and 24 participated in the interventional phase. The 24 biomarker evaluable women had a median baseline BMI of 34.2 kg/m2 and lost a median of 11 {\%} of their initial weight. Significant tissue biomarker modulation after the 6-month intervention was noted for Ki-67 (if restricted to the 15 women with any Ki-67 at baseline, p = 0.041), adiponectin to leptin ratio (p = 0.003); and cyclin B1 (p = 0.001), phosphorylated retinoblastoma (p = 0.005), and ribosomal S6 (p = 0.004) proteins. Favorable modulation for serum markers was observed for sex hormone-binding globulin (p < 0.001), bioavailable estradiol (p < 0.001), bioavailable testosterone (p = 0.033), insulin (p = 0.018), adiponectin (p = 0.001), leptin (p < 0.001), the adiponectin to leptin ratio (p < 0.001), C-reactive protein (p = 0.002), and hepatocyte growth factor (p = 0.011). When subdivided by <10 or >10 {\%} weight loss, change in percent total body and android (visceral) fat, physical activity, and the majority of the serum and tissue biomarkers were significantly modulated only for women with >10 {\%} weight loss from baseline. Some factors such as serum PAI-1 and breast tissue pS2 (estrogen-inducible gene) mRNA were not significantly modulated overall but were when considering only those with >10 {\%} weight loss. In conclusion, a median weight loss of 11 {\%} over 6 months resulted in favorable modulation of a number of anthropomorphic, breast tissue and serum risk and mechanistic markers. Weight loss of 10 {\%} or more should likely be the goal for breast cancer risk reduction studies in obese women.",
keywords = "Breast risk biomarkers with weight loss, Energy balance, RPFNA",
author = "Fabian, {Carol J.} and Kimler, {Bruce F.} and Donnelly, {Joseph E.} and Sullivan, {Debra K.} and Klemp, {Jennifer R.} and Petroff, {Brian K.} and Phillips, {Teresa A.} and Trina Metheny and Sonya Aversman and Yeh, {Hung Wen} and Zalles, {Carola M.} and Gordon Mills and Hursting, {Stephen D.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/s10549-013-2730-8",
language = "English (US)",
volume = "142",
pages = "119--132",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women

AU - Fabian, Carol J.

AU - Kimler, Bruce F.

AU - Donnelly, Joseph E.

AU - Sullivan, Debra K.

AU - Klemp, Jennifer R.

AU - Petroff, Brian K.

AU - Phillips, Teresa A.

AU - Metheny, Trina

AU - Aversman, Sonya

AU - Yeh, Hung Wen

AU - Zalles, Carola M.

AU - Mills, Gordon

AU - Hursting, Stephen D.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - We conducted a phase II feasibility study of a 6-month behavioral weight loss intervention in postmenopausal overweight and obese women at increased risk for breast cancer and the effects of weight loss on anthropomorphic, blood, and benign breast tissue biomarkers. 67 women were screened by random peri-areolar fine-needle aspiration, 27 were registered and 24 participated in the interventional phase. The 24 biomarker evaluable women had a median baseline BMI of 34.2 kg/m2 and lost a median of 11 % of their initial weight. Significant tissue biomarker modulation after the 6-month intervention was noted for Ki-67 (if restricted to the 15 women with any Ki-67 at baseline, p = 0.041), adiponectin to leptin ratio (p = 0.003); and cyclin B1 (p = 0.001), phosphorylated retinoblastoma (p = 0.005), and ribosomal S6 (p = 0.004) proteins. Favorable modulation for serum markers was observed for sex hormone-binding globulin (p < 0.001), bioavailable estradiol (p < 0.001), bioavailable testosterone (p = 0.033), insulin (p = 0.018), adiponectin (p = 0.001), leptin (p < 0.001), the adiponectin to leptin ratio (p < 0.001), C-reactive protein (p = 0.002), and hepatocyte growth factor (p = 0.011). When subdivided by <10 or >10 % weight loss, change in percent total body and android (visceral) fat, physical activity, and the majority of the serum and tissue biomarkers were significantly modulated only for women with >10 % weight loss from baseline. Some factors such as serum PAI-1 and breast tissue pS2 (estrogen-inducible gene) mRNA were not significantly modulated overall but were when considering only those with >10 % weight loss. In conclusion, a median weight loss of 11 % over 6 months resulted in favorable modulation of a number of anthropomorphic, breast tissue and serum risk and mechanistic markers. Weight loss of 10 % or more should likely be the goal for breast cancer risk reduction studies in obese women.

AB - We conducted a phase II feasibility study of a 6-month behavioral weight loss intervention in postmenopausal overweight and obese women at increased risk for breast cancer and the effects of weight loss on anthropomorphic, blood, and benign breast tissue biomarkers. 67 women were screened by random peri-areolar fine-needle aspiration, 27 were registered and 24 participated in the interventional phase. The 24 biomarker evaluable women had a median baseline BMI of 34.2 kg/m2 and lost a median of 11 % of their initial weight. Significant tissue biomarker modulation after the 6-month intervention was noted for Ki-67 (if restricted to the 15 women with any Ki-67 at baseline, p = 0.041), adiponectin to leptin ratio (p = 0.003); and cyclin B1 (p = 0.001), phosphorylated retinoblastoma (p = 0.005), and ribosomal S6 (p = 0.004) proteins. Favorable modulation for serum markers was observed for sex hormone-binding globulin (p < 0.001), bioavailable estradiol (p < 0.001), bioavailable testosterone (p = 0.033), insulin (p = 0.018), adiponectin (p = 0.001), leptin (p < 0.001), the adiponectin to leptin ratio (p < 0.001), C-reactive protein (p = 0.002), and hepatocyte growth factor (p = 0.011). When subdivided by <10 or >10 % weight loss, change in percent total body and android (visceral) fat, physical activity, and the majority of the serum and tissue biomarkers were significantly modulated only for women with >10 % weight loss from baseline. Some factors such as serum PAI-1 and breast tissue pS2 (estrogen-inducible gene) mRNA were not significantly modulated overall but were when considering only those with >10 % weight loss. In conclusion, a median weight loss of 11 % over 6 months resulted in favorable modulation of a number of anthropomorphic, breast tissue and serum risk and mechanistic markers. Weight loss of 10 % or more should likely be the goal for breast cancer risk reduction studies in obese women.

KW - Breast risk biomarkers with weight loss

KW - Energy balance

KW - RPFNA

UR - http://www.scopus.com/inward/record.url?scp=84888222805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888222805&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2730-8

DO - 10.1007/s10549-013-2730-8

M3 - Article

VL - 142

SP - 119

EP - 132

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -